Redwire Secures $25M NASA Contract for Biotech Services and On-Orbit Operations Support

Redwire has been awarded a $25 million NASA contract to provide biotechnology and on-orbit operations support for the International Space Station. The company will manage, integrate, and facilitate experiments and support on-orbit operations for NASA-funded research investigations aboard the ISS. Redwire has also been issued a $2.5 million task order from NASA's In Space Production Applications program to support additional drug development investigations using their PIL-BOX technology.

Redwire Corporation (NYSE: RDW), a leading provider of space and defense technology solutions, has been awarded a $25 million NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract. This five-year agreement will allow Redwire to fulfill future task orders for biotechnology facilities, on-orbit operations support, mission integration, and related services for the International Space Station (ISS). The contract, announced on August 28, 2025, carries a ceiling of $25 million [1][2].

Under this contract, Redwire has already been issued a $2.5 million task order from NASA’s In Space Production Applications (InSPA) program. This order supports additional drug development investigations on the ISS using Redwire’s PIL-BOX technology. The PIL-BOX is a turnkey solution designed to manage, integrate, and facilitate experiments and support on-orbit operations for NASA-funded research investigations aboard the ISS [1][2].

John Vellinger, President of Redwire In-Space Industries, commented on the award, stating, “Redwire’s biotechnology facilities have been integral to NASA’s ISS research strategy, supporting an increased throughput of critical scientific research and expanding on-orbit capabilities for drug development, cancer research, and tissue engineering.” He expressed gratitude for NASA’s trust in Redwire’s proven biotechnology capabilities and experience, and reaffirmed the company’s commitment to enabling new discoveries for NASA and the ISS science community [1][2].

Redwire has extensive experience in microgravity research and development, having flown hundreds of experiments on both the Space Shuttle and the ISS. The company’s microgravity technology supports space biotechnology and pharmaceutical development, helping companies unlock new insights for potential therapeutics and paving the way for future commercial space stations [1][2].

Redwire recently formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit to create new and reformulated pharmaceuticals on Earth. This initiative underscores Redwire’s commitment to advancing space-based research and its potential to revolutionize pharmaceutical development [1][2].

References:
[1] https://www.stocktitan.net/news/RDW/redwire-awarded-25-million-single-award-idiq-contract-by-nasa-to-vl0han4bnvlt.html
[2] https://www.marketscreener.com/news/redwire-awarded-25-million-single-award-idiq-contract-by-nasa-to-provide-biotechnology-and-support-ce7c50dfde81fe22